 | | Vol. 13.03 – 28 January, 2021 |
| |
|
|
| Scientists tested a time-restricted feeding (TRF) approach on mouse models of obesity-driven postmenopausal breast cancer. They showed that TRF abrogated the obesity-enhanced mammary tumor growth in two orthotopic models in the absence of calorie restriction or weight loss.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators addressed the early period of dormancy when breast cancer cells enter bone marrow at the perivascular region to begin the transition into cancer stem cells, which they proposed as the final step in dormancy.
[Cancer Research] |
|
|
|
| Researchers explored the association of breast cancer subtypes with different metabolic phenotypes and identified isocitrate dehydrogenase 2 (IDH2) as a key player in TNBC and HER2.
[Cancer Research] |
|
|
|
| The authors performed a genome-wide CRISPR/Cas9 screen in MCF7 breast cancer cells to identify genes whose loss of function reversed Beclin 1-dependent inhibition of cellular proliferation.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists provided strong evidence that epithelial-to-mesenchymal transition (EMT) was orchestrated by coordinated expression of several EMT- transcription factors and established ZEB1 as a key master regulator of EMT and metastasis in breast cancer.
[Molecular Cancer Research] |
|
|
|
| Overexpression of decorin in inflammatory breast cancer (IBC) cells markedly decreased migration, invasion, and cancer stem cells in vitro and inhibited tumor growth and metastasis in IBC xenograft mouse models.
[Communications Biology] |
|
|
|
| The authors identified the lncRNA transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy, employing 1758 single cells from three extinction and three persistence TNBC patients.
[Cell Death Discovery] |
|
|
|
| Investigators found that triptonide inhibited human TNBC cell growth in vitro and the growth of TNBC xenograft mammary tumors.
[Scientific Reports] |
|
|
|
| Researchers tested the hypothesis that the circadian-related herb valerian could inhibit breast cancer cell growth and explored epigenetic changes associated with valeric acid treatment.
[Scientific Reports] |
|
|
|
|
| The current status of antioxidant use in cancer treatment is examined in order to highlight the importance of the selective use of N-acetylcysteine for specific types of cancer.
[Antioxidants] |
|
|
|
| Scientists provide a comprehensive discussion of potential epigenetic mechanisms of curcumin in reversing altered patterns of DNA methylation in breast cancer that is the most commonly diagnosed cancer and the leading cause of cancer death among females worldwide.
[Nutrients] |
|
|
|
|
| Celcuity, Inc. announced a clinical trial collaboration with Sarah Cannon Research Institute, the research arm of Sarah Cannon, and Pfizer Inc., a global biopharmaceutical company, to conduct a Phase II clinical trial.
[Celcuity, Inc.] |
|
|
|
| Zymeworks, Inc. announced that the company has begun enrolling patients into the expansion cohort portion of the ongoing Phase I clinical trial for ZW49, its novel HER2-targeted antibody-drug conjugate.
[Zymeworks, Inc.] |
|
|
|
|
| February 3 – 23, 2021
Virtual |
|
|
|
|
|
| | Gilead Sciences, Inc. – London, England, United Kingdom |
|
|
|
| | Gilead Sciences, Inc. – Munich, Germany |
|
|
|
| | Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| | Salk Institute of Biological Studies – La Jolla, California, United States |
|
|
|
| | Salk Institute of Biological Studies – La Jolla, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
